South Korea Botulinum Toxin Type A Market To Reach $386.9 Million By 2030

South Korea Botulinum Toxin Type A Market Growth & Trends

The South Korea botulinum toxin type A market size is anticipated to reach USD 386.9 million by 2030 and expanding at a CAGR of 10.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising aesthetic consciousness among the South Korean population fuels the demand for the market. South Koreans place a high value on physical appearance, with a strong cultural emphasis on beauty and youthfulness. This societal trend has led to an increasing demand for non-invasive cosmetic procedures, including botulinum toxin treatments, to enhance and maintain one's appearance. For instance, the popularity of K-beauty standards and the influence of media and celebrities have heightened awareness and acceptance of aesthetic treatments. This growing focus on aesthetics is not limited to any specific age group, as both younger and older demographics are seeking treatments to address their cosmetic concerns, further driving the market for botulinum toxin products.

The growing consumer preference for health, safety, and authenticity has driven a strong focus on natural and organic products. According to the International Trade Administration article published in September 2023, despite a slight decrease in total local production and exports in 2022, South Korea remains one of the top 10 beauty markets globally. This trend presents new opportunities in the botulinum toxin type A market as consumers increasingly seek safe and natural cosmetic solutions. Additionally, the Ministry of Food & Drug Safety (MFDS) has introduced guidelines for natural and organic cosmetics, supporting the development and growth of this niche market within the botulinum toxin sector.

 Request a free sample copy or view report summary: South Korea Botulinum Toxin Type A Market Report

South Korea Botulinum Toxin Type A Market Report Highlights

• In terms of application, the upper face segment held the largest share of 51.85% in 2023 and is anticipated to grow at fastest growth rate over the forecast period owing to increasing demand for aesthetic treatments aimed at reducing wrinkles in areas such as the forehead, glabella, and crow's feet.

• Based on gender, the female segment held the largest share of 82.02% as women in South Korea often experience early signs of aging and skin dullness, influenced by hormonal fluctuations such as declining estrogen levels.

• Based on age, 31 to 59 Years segment held the largest share of over 44.35% in 2023. This age group is typically more concerned with signs of aging such as wrinkles and fine lines, making botulinum toxin type A injections a popular choice for rejuvenating facial appearance.

• Based on end use, the specialty clinics & aesthetic centers segment held the largest share of over 42.99% in 2023. These facilities provide a range of cosmetic procedures under one roof, catering to diverse patient needs. Moreover, clinics employ skilled dermatologists and aesthetic practitioners who specialize in facial rejuvenation and cosmetic enhancements.

South Korea Botulinum Toxin Type A Market Segmentation

Grand View Research has segmented the South Korea Botulinum Toxin Type A market based on application, gender, age, and end-use.

South Korea Botulinum Toxin Type A Application Category Outlook (Revenue, USD Million; 2018 - 2030)

• Upper Face

  • Glabellar Wrinkles

  • Forehead Wrinkles

  • Crow’s Feet

• Mid Face

• Lower Face

• Body

South Korea Botulinum Toxin Type A Gender Outlook (Revenue, USD Million; 2018 - 2030)

• Female

• Male

South Korea Botulinum Toxin Type A Age Outlook (Revenue, USD Million; 2018 - 2030)

• Below 30 Years

• 31 to 59 Years

• Over 60 Years

South Korea Botulinum Toxin Type A End-use Outlook (Revenue, USD Million; 2018 - 2030)

• Hospitals

• Specialty Clinics & Aesthetic Centers

• Medspas

List of Key Players in the South Korea Botulinum Toxin Type A Market

• Hugel

• Medytox

• Daewoong

• Galderma

• Ipsen

• Huons Global

• Pharma Research BIO

• AbbVie